Skip to main content
MANE
NYSE Life Sciences

Averill Funds Sell $80.4M Veradermics Stock and Exercise 300K Warrants

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$102.82
Mkt Cap
$4.296B
52W Low
$32
52W High
$131.24
52W Position info
221% above low
Off High info
22% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

MANE has more than doubled off its 52-week low of $32.

Summary

Averill Master Fund and Averill Madison Master Fund sold $80.4 million of Veradermics stock and exercised 300,000 pre-funded warrants, adding to recent insider selling pressure.


Key Events · Ownership and Investor Activity · MANE

  • Averill Funds Sell $80.4M

    Averill Master Fund sold 690,601 shares and Averill Madison Master Fund sold 59,399 shares on August 19, 2026, at $107.25 per share, totaling approximately $80.4 million.

  • Warrant Exercises Add 300K Shares

    On August 20, 2026, Averill Master Fund exercised 149,000 pre-funded warrants and Averill Madison Master Fund exercised 151,000 pre-funded warrants at $0.00001 per share, adding 300,000 shares to the float.

  • Insider Selling Wave Continues

    This sale follows $103.1 million in open-market insider selling over the past 90 days, including a $15 million planned sale by CEO Reid Waldman and a $10.7 million sale by Director John W. Childs.

  • Ownership Stakes Reduced

    After these transactions, Averill Master Fund holds 3,718,970 shares (8.8%), Averill Madison Master Fund holds 612,033 shares (1.5%), and Montanova Capital reports aggregate beneficial ownership of 3,718,970 shares (8.8%).


Analysis · MANE · Life Sciences

The Averill funds, managed by Montanova Capital, sold 750,000 shares at $107.25 on August 19, 2026, for approximately $80.4 million, and then exercised pre-funded warrants for 300,000 shares at a nominal price on August 20. This continues a wave of insider selling that has totaled over $103 million in the past 90 days, including a $15 million planned sale by the CEO. The warrant exercises add 300,000 shares to the float, increasing potential supply pressure.

At the time of this filing, MANE was trading at $102.82 on NYSE in the Life Sciences sector, with a market capitalization of approximately $4.3B. The 52-week trading range was $32.00 to $131.24. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MANE - Latest Insights

MANE
Aug 21, 2026, 6:11 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $102.82
Real-time Price: $102.82 info
Change: $0 (0%) info
Market Cap: $4.296B info
MANE
Aug 17, 2026, 5:30 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $108.22
Real-time Price: $102.82 info
Change: -$5.40 (-5%) info
Market Cap: $4.296B info
MANE
Aug 11, 2026, 7:40 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $110.00
Real-time Price: $102.82 info
Change: -$7.18 (-7%) info
Market Cap: $4.296B info
MANE
Aug 07, 2026, 5:08 PM EDT
Filing Type: S-1
Importance Score:
7
Price at Filing: $116.00
Real-time Price: $102.82 info
Change: -$13.18 (-11%) info
Market Cap: $4.296B info
MANE
Jul 15, 2026, 9:03 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $118.32
Real-time Price: $102.82 info
Change: -$15.50 (-13%) info
Market Cap: $4.296B info